HOME >> BIOLOGY >> NEWS
Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure

(Philadelphia, PA) The events that lead to cardiac hypertrophy, the enlargement of heart muscle cells, may be stopped by histone deacetylase (HDAC) inhibitors, a class of therapeutic agents currently under development as cancer drugs, according to researchers at the University of Pennsylvania School of Medicine. Cardiac hypertrophy is one of the leading causes of congestive heart failure, the most common diagnosis given for discharged hospital patients in the United States.

In the September issue of Journal of Clinical Investigation, the Penn researchers suggest novel genetic causes for and new therapeutic agents against cardiac hypertrophy and heart failure. Furthermore, the researchers demonstrate that anti-HDAC drugs can block the development of hypertrophy in animal models.

"In our studies, we determined that valproic acid, an HDAC inhibitor used to treat seizure disorders, is effective in preventing heart muscle cells from enlarging," said Jonathan A. Epstein, MD, Associate Professor in the division of Cardiovascular Medicine within Penn's Department of Medicine. "In recent years, drug companies have also begun developing more advanced HDAC inhibitors to treat cancer. These HDAC inhibitors may be among the first known medications to prevent cardiac hypertrophy."

Cardiac hypertrophy can be a healthy physiological response to events, such as aerobic exercise, where heart cells grow larger like any other well-conditioned muscle. Pathological hypertrophy, however, may result from genetic mutation or, most commonly, from the consequences of an unhealthy cardiovascular system.

"The exertion of pushing blood against high resistance in the setting of high blood pressure or overcompensation for heart muscle lost during a heart attack can cause heart muscle cells to enlarge," said Epstein. "While it might be helpful at first, hypertrophy can increase the stress placed on the heart and begin a downward spiral of events that ultimately leads
'"/>

Contact: Greg Lester
lesterg@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
15-Sep-2003


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... June 04, 2019 , ... Lajollacooks4u is delighted to announce it ... which honors hospitality excellence, is given only to businesses that have achieved consistently outstanding ... consecutive years. , To qualify for the Certificate of Excellence –- an ...
(Date:6/1/2019)... ... May 31, 2019 , ... The University ... recently invested in BioFactura’s $6M Series B Financing Round. , “With the ... investors who bring significant financial and business resources to bear as we advance ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers from Ambry ... documented significant differences in the prevalence of hereditary genetic mutations, also called germline ... White women. Results will be presented at the 2019 American Society of Clinical ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... California (PRWEB) , ... May ... ... of our patent applications from the USPTO providing proprietary interest to our ... METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including ...
(Date:5/22/2019)... ... 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation Management ... co-led by Astanor Ventures and Talis Capital with participation from ... Fund . The company has raised $11.75m to date and will use the new ...
(Date:5/14/2019)... ... May 13, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is ... redesigned website aims to improve LDA’s ability to communicate directly with the marketplace; ...
(Date:5/4/2019)... Brazil (PRWEB) , ... May 03, 2019 , ... ... given by the President of the Dakila Pesquisas Association, the scientist and ufologist ... Councilmen 2019, in Brasília (DF). Urandir detailed the results of some research carried ...
Breaking Biology Technology:
Cached News: